// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Low expression of mutant Ubiquilin-2 exacerbates ALS/FTD features in a TDP-43 mouse model (P4.431)

Vincent Picher-Martel - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

TDP-43

Delivering Education to Patients with MS - a Survey of Canadian Neurologists (P4.402)

Olga Lekontseva - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Quantitative Myelin Measurement in Brain White Matter Tracts of Rare Progressive Solitary Sclerosis, Compared to Multiple Sclerosis and Healthy Control Subjects (P1.086)

Lisa Eunyoung Lee - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

N/A

Safety and efficacy of IV cladribine versus alemtuzumab in aggressive multiple sclerosis: a retrospective cohort study (P1.368)

Gauruv Bose - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Alemtuzumab

Communication Priorities in Spontaneous Intracerebral Hemorrhage (CPsICH): A Survey-based Study Incorporating Patient and Physician Perspectives (P6.335)

Jonathan Krett - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Continuous Bedside Subhairline EEG in Comatose Survivors of Cardiac Arrest (P4.343)

S Cooley - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Serum and CSF Neuroflament Light Chain levels normalise following Bone Marrow Transplant in MS Patients (P5.036)

Simon Thebault - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Regulation of HMGB1 inflammation in patients with ischemic stroke by microRNA (S15.006)

Glen Jickling - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

How experts diagnose TIA: A systematic review (P5.256)

Tess Fitzpatrick - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Phenotype and Cognitive Profile in ELOVL4-Associated SCA34 (P6.089)

Marie Beaudin - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Healthcare-Associated Infections after Spontaneous Subarachnoid Hemorrhage (P6.328)

Najayeb S. Alabdulraheem - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

MS in immigrants to Canada in the McDonald era: Increasing prevalence and risk factors (S44.001)

Dalia Rotstein - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characteristics of periventricular nodules in patients with 22q11. 2 deletion syndrome (P2.284)

Arezoo Rezazadeh - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Age-Dependent White Matter Inflammation and Cognitive Impairment in the TgAPP21 Rat Model of Alzheimer Disease (P2.184)

Alexander Levit - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Pregabalin and Lidocaine to Alter Neuropathic Pain After Breast Cancer Surgery: Results of a Pilot Factorial-Design Randomized Controlled Trial

James Khan - American Academy of Pain Medicine (AAPM) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pregabalin

STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA

Dillon McKenna - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

TMOD-38. PRODUCTION OF D-2-HYDROXYGLUTARATE IN SACCHAROMYCES CEREVISIAE LEADS TO GROWTH IMPAIRMENT AND DECREASED SURVIVAL

Sophie Fiola - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Low-grade gliomas

N/A

RDNA-01. TUBULIN AND MICROTUBULES AS MOLECULAR TARGETS FOR TTFIELD THERAPY

Aarat Kalra - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

PDTM-28. AN OTX2-PAX3 SIGNALLING AXIS REGULATES GROUP 3 MEDULLOBLASTOMA CELL FATE

Jennifer Chan - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Medulloblastoma

N/A

TMOD-41. ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF BRAIN METASTASIS: PLATFORMS FOR PRECISION ONCOLOGY AND UNDERSTANDING TUMOR BIOLOGY

Matthew Dankner - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Brain metastasis

Methadone hydrochloride

Copyright © 2026. QuantiNova All rights reserved